Despite Challenging Global Economic Conditions, Nucletron Surpassed
Projections for the First Half Year
VEENENDAAL, the Netherlands, Sept. 3 /CNW/ - Nucletron, a global leader
in radiation oncology, today announced strong financial results over the first
half year of 2009. Despite challenging global economic conditions, Nucletron
surpassed projections for the first half year.
Net sales amounted to EUR 51.2 million, a 3% growth on like-for-like
basis compared to the first half of 2008. EBITDA in the first half of 2009
amounted to EUR 6.3 million, a 53% increase compared to EUR 4.1 million over
the same period last year. As a result of the positive developments Nucletron
expects full year EBITDA to increase to EUR 19.0 million.
Jos Lamers, chief executive officer of Nucletron, comments: "Over the
first six months of 2009, we have seen the results of our improved focus on
innovation and our increased marketing efforts. Our senior management team is
at full strength after the appointment of three new team members with a blue
chip background. Combining our strength in marketing and sales with the
research & development capabilities of Isodose Control will make Nucletron one
of the global leaders in brachytherapy. Given our many upcoming product
releases in the months ahead, we are on track to outperform our 2009 goals."
Among the several advancements made in the first half of 2009, Nucletron
partnered with Advanced Radiation Therapy (ART) to offer a revolutionary
solution for treating breast cancer. AccuBoost allows clinicians to use
image-guidance, as used in a standard mammography, to pinpoint radiation
directly to the tumour site. This allows for much better accuracy in targeting
the radiation to the cancerous area, while protecting the patients' healthy
organs during treatment.
The business collaboration with Isodose Control is now in place. The
partnership allows clinicians to benefit from Nucletron's leadership and
strength in brachytherapy with Isodose Control's track record of innovation.
Additionally, Nucletron launched its latest evolution in treatment
planning for radiotherapy. Model-based segmentation in Oncentra MBS and
volumetric modulated arc therapy with Oncentra VMAT ensure quality, while
dramatically reducing the time needed to create treatment plans.
Visit our website http://www.nucletron.com
Nucletron is a global leader in Radiation Oncology, working with clinical
teams to realize innovative solutions that improve patient care. Nucletron
strives to offer the best possible choice of radiation modalities through
integrated products, software and services. Critical to the Nucletron
philosophy is the establishment of close working relationships with individual
clinical teams - reconfiguring traditional boundaries between customer and
solution provider. Many Nucletron employees have clinical experience
delivering oncology care, providing an in-depth understanding of the complex
needs of clinicians.
For further information:
For further information: Nucletron B.V., Jos Lamers, CEO, Office:
+31-3185-57250, Mobile: +31-6538-53424, email@example.com